A “tumor-on-a-chip” model is giving scientists a live look at how pancreatic cancer can recruit the body’s own immune cells to help tumors survive. The study reveals possible new targets to weaken the cancer’s defenses and make treatments work better.
A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.
